Mary, Author at Abcuro

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

October 4, 2022

T-LGLL is an autoimmune disorder characterized by cytotoxic T lymphocytes which attack neutrophils and red blood cell precursors Newton, Massachusetts, October 4, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of a Phase

October 4, 2022

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic LeukemiaPress Releases

Abcuro Appoints Alex Martin as Chief Executive Officer

October 3, 2022

Industry veteran brings extensive experience in building and leading biopharmaceutical companies Newton, Massachusetts, October 3, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Alex Martin as Chief Executive Officer. He brings to

October 3, 2022

Abcuro Appoints Alex Martin as Chief Executive OfficerPress Releases

Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer

June 23, 2022

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

June 23, 2022

Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board ObserverPress Releases

Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical Officer

June 21, 2022

Industry veteran brings extensive clinical development experience in immunology, immuno-oncology, and rare diseases to leadership team Newton, Massachusetts, June 21, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of H. Jeffrey Wilkins, M.D.,

June 21, 2022

Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical OfficerPress Releases

Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022

June 7, 2022

Newton, Massachusetts, June 7, 2022, Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the presentation of additional clinical results from its ongoing Phase 1 clinical trial of its lead product candidate ABC008 in patients with inclusion

June 7, 2022

Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022Press Releases